Viewing nowCombinationTeramet XR Sustained Release Tablet 100/1000 mg
Sitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Teragen Itex Co., Ltd.

MFDS item code 202202014 · Approved 2022.05.13 · Insurance code 698504790
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine is used to assist patients with type 2 diabetes in controlling their blood sugar. It can be effectively managed when used together with therapeutic methods such as diet control and exercise. The two ingredients, sitagliptin and metformin, work together to lower and control blood sugar. This helps in preventing complications caused by diabetes. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently being treated with metformin: For patients with no prior experience of pharmacologic treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients being treated with metformin: For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current dose of metformin. Patients switching from concomitant therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. Patients who were receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablet once daily. 3. Patients who do not achieve adequate blood glucose control with concomitant therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, provided that the following dosage adjustment is made. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.
This medicine contains sitagliptin and metformin and is used for the treatment of diabetes. Serious allergic reactions may occur during the use of this medicine, so if rashes, hives, difficulty in breathing, or swelling of the face or lips occur, stop taking the medicine immediately and inform your healthcare provider. There is a possibility of acute pancreatitis, which is inflammation of the pancreas, so consult a doctor immediately if abdominal pain, vomiting, or severe abdominal pain occurs. This medicine should not be administered to patients with impaired kidney function, acute heart disease, severe infections, or dehydration. In particular, the medication should be temporarily discontinued before and after tests using iodine contrast agents, resuming only after confirming normal kidney function. It is not safe for pregnant women or women who may become pregnant, and lactating women should avoid this medication. Elderly patients or those with compromised kidney function should adjust the dosage and have regular kidney function tests. During the use of this medication, be aware of signs of hypoglycemia, especially when used in conjunction with insulin or sulfonylurea medications, as the risk of hypoglycemia may increase. Due to the metformin component, there is a rare risk of lactic acidosis, a serious metabolic disorder, so if symptoms such as vomiting, diarrhea, muscle pain, weakness, or difficulty breathing occur, inform a healthcare provider immediately. This medication is not recommended for patients with liver dysfunction, and excessive alcohol consumption should be avoided as it may increase the risk of lactic acidosis. Additionally, the use of this medicine may decrease vitamin B12 levels, necessitating regular blood tests for monitoring. Patients scheduled for surgery should discontinue this medication 48 hours prior to the surgery and may resume after confirming that they can consume orally and that kidney function is normal. This medicine may interact with several other medications, so if you are taking other medications, be sure to inform your healthcare provider and closely monitor blood sugar control. Finally, the safety and efficacy of this medicine have not been established in children under 18 years of age, so it should not be administered to pediatric patients.
Severe hypersensitivity, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, hypoglycemia, severe hypoglycemia, acute renal failure, elevated liver enzymes, rash, urticaria, cutaneous vasculitis, arthritis with severe pain and disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius to safely maintain its effectiveness.
Bright blue, oval, double-convex sustained-release film-coated tablets
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Teragen Itex Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.